In this study, we characterized the effects of LA-12 on tumor cell lines possessing wild type p53 and on p53-deficient/mutant cell lines and the results were compared to those obtained using cisplatin. We have determined changes of p53 levels, of its transcriptional activity, of its posttranscriptional modifications and the effect of the treatment on the cell cycle, on the induction of apoptosis and on gene expression. LA-12 induces weak accumulation of both transcriptionally active p53 tumor suppressor and of p21(WAF1/CIP1) protein. LA-12 and cisplatin also significantly differ in their effects on apoptosis and cell cycle and on gene expression spectra in studied cell lines. LA-12 induces higher apoptosis levels in comparison with those induced by cisplatin, especially in p53-deficient H1299 cells and in MCF-7DD cells with transcriptionally inactive p53. We suggest that LA-12-mediated apoptosis is not fully dependent on p53. This confirms the therapeutic potential of LA-12 as a more potent cytostatic agent for both tumor cells expressing wild type p53 and for p53-deficient or mutant cells.

Department of Oncological and Experimental Pathology Masaryk Memorial Cancer Institute Zlutý kopec 7 656 53 Brno Czech Republic

Zobrazit více v PubMed

Br Med Bull. 1994 Jul;50(3):582-99 PubMed

Invest New Drugs. 2007 Oct;25(5):435-43 PubMed

Genes Dev. 1998 Sep 15;12(18):2831-41 PubMed

Am J Pathol. 1996 Mar;148(3):825-35 PubMed

Anticancer Drugs. 2008 Apr;19(4):369-79 PubMed

Nat Rev Cancer. 2004 Oct;4(10):793-805 PubMed

Genes Dev. 1998 Oct 1;12(19):2973-83 PubMed

Cancer Res. 1994 Mar 1;54(5):1169-74 PubMed

Int J Pharm. 2005 Jan 6;288(1):123-9 PubMed

Cancer Res. 1997 Aug 15;57(16):3390-4 PubMed

Cell. 1993 Nov 19;75(4):817-25 PubMed

Genes Dev. 1996 May 1;10(9):1054-72 PubMed

Br J Cancer. 1999 Aug;80(11):1689-96 PubMed

J Biol Chem. 1998 Apr 17;273(16):9357-60 PubMed

Oncogene. 1995 Feb 16;10(4):671-80 PubMed

J Mol Biol. 1995 Apr 21;248(1):58-78 PubMed

Prog Nucleic Acid Res Mol Biol. 2002;71:1-68 PubMed

Cancer Chemother Pharmacol. 1991;27(6):464-71 PubMed

Cell. 1994 Mar 25;76(6):1013-23 PubMed

Cell. 1997 Feb 7;88(3):323-31 PubMed

Br J Cancer. 1998 Dec;78(11):1404-6 PubMed

J Immunol Methods. 1992 Jul 6;151(1-2):237-44 PubMed

Oncogene. 1998 Aug 27;17(8):1045-52 PubMed

Gynecol Oncol. 2006 Jul;102(1):32-40 PubMed

Cell Mol Life Sci. 1999 Jan;55(1):76-87 PubMed

Nucleic Acids Res. 1992 Jan 25;20(2):267-72 PubMed

Biochem Pharmacol. 2005 Feb 1;69(3):373-83 PubMed

Int J Radiat Biol. 1998 Dec;74(6):729-37 PubMed

Cancer Res. 1992 May 1;52(9 Suppl):2732s-2736s PubMed

FASEB J. 1998 Jul;12(10):791-9 PubMed

Int J Cancer. 1997 Nov 27;73(5):757-62 PubMed

J Med Chem. 2004 Jan 29;47(3):761-3 PubMed

Cisplatin or LA-12 enhance killing effects of TRAIL in prostate cancer cells through Bid-dependent stimulation of mitochondrial apoptotic pathway but not caspase-10

Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer Cells

Loss of PTEN Facilitates Rosiglitazone-Mediated Enhancement of Platinum(IV) Complex LA-12-Induced Apoptosis in Colon Cancer Cells

Higher anti-tumour efficacy of platinum(IV) complex LA-12 is associated with its ability to bypass M-phase entry block induced in oxaliplatin-treated human colon cancer cells

The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo

The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin